Skip to content

Interest Income at other companies

Incyte logo
IncyteINCY
$33.69M+46.9%
Exelixis logo
ExelixisEXEL
$16.13M-15.5%
BridgeBio Pharma logo
BridgeBio PharmaBBIO
$6.25M+16.0%
Roivant Sciences logo
Roivant SciencesROIV
$41.18M-24.6%
CG Oncology logo
CG OncologyCGON
Apogee Therapeutics, Inc. logo
Apogee Therapeutics, Inc.APGE

Other financials

Income statement

See full
Operating income-$103.6M-38.3%
Net income-$97.4M-35.2%
EPS (diluted)-$0.53-1.9%

Balance sheet

See full
Cash & equivalents$241.2M+91.4%
Total debt$15.5M-9.4%
Total equity$607.7M+177%
Total assets$903.0M+218%

Cash flow

See full
Operating cash flow-$86.9M-30.6%
CapEx$449.0K-17.9%
Free cash flow-$87.3M-30.2%

Valuation

See full
Market cap$5.9B+816%
Enterprise value$5.68B+951%
P/S749.8×

Profitability

See full
Operating margin-1,044.3%
Net margin-950.4%
FCF margin-184.7%

Returns & leverage

See full
Return on equity-85.7%+1.7pp
Debt / equity-0.1×
Current ratio15.1×+10.0×

Where this comes from

Reported directly by Cogent Biosciences, Inc. in its filing.

Tagged under the XBRL concept us-gaap:InvestmentIncomeInterest.

The official record: Cogent Biosciences, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Cogent Biosciences, Inc.'s interest income.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Cogent Biosciences, Inc.'s interest income?
Cogent Biosciences, Inc. (COGT) reported interest income of $7.61M in Q1 2026.
How has Cogent Biosciences, Inc.'s interest income changed year-over-year?
Cogent Biosciences, Inc.'s interest income increased by 157.7% year-over-year, from $2.95M to $7.61M.
What is the long-term trend for Cogent Biosciences, Inc.'s interest income?
Over 4 years (2021 to 2025), Cogent Biosciences, Inc.'s interest income has grown at a 136.8% compound annual growth rate (CAGR), from $467K to $14.69M.
What does interest income mean?
Income earned from interest-bearing assets including cash deposits, money market funds, treasury securities, corporate bonds, and customer financing receivables.